JP2023123726A5 - - Google Patents

Download PDF

Info

Publication number
JP2023123726A5
JP2023123726A5 JP2023105929A JP2023105929A JP2023123726A5 JP 2023123726 A5 JP2023123726 A5 JP 2023123726A5 JP 2023105929 A JP2023105929 A JP 2023105929A JP 2023105929 A JP2023105929 A JP 2023105929A JP 2023123726 A5 JP2023123726 A5 JP 2023123726A5
Authority
JP
Japan
Prior art keywords
seq
hvr
amino acid
acid sequence
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2023105929A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023123726A (ja
Filing date
Publication date
Priority claimed from JP2019559378A external-priority patent/JP2020518584A/ja
Application filed filed Critical
Publication of JP2023123726A publication Critical patent/JP2023123726A/ja
Publication of JP2023123726A5 publication Critical patent/JP2023123726A5/ja
Withdrawn legal-status Critical Current

Links

JP2023105929A 2017-05-02 2023-06-28 細胞傷害誘導治療剤 Withdrawn JP2023123726A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2017091955 2017-05-02
JP2017091955 2017-05-02
JP2019559378A JP2020518584A (ja) 2017-05-02 2018-05-02 細胞傷害誘導治療剤
PCT/JP2018/017495 WO2018203567A1 (en) 2017-05-02 2018-05-02 Cytotoxicity-inducing therapeutic agent

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019559378A Division JP2020518584A (ja) 2017-05-02 2018-05-02 細胞傷害誘導治療剤

Publications (2)

Publication Number Publication Date
JP2023123726A JP2023123726A (ja) 2023-09-05
JP2023123726A5 true JP2023123726A5 (enExample) 2025-08-05

Family

ID=64016153

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019559378A Pending JP2020518584A (ja) 2017-05-02 2018-05-02 細胞傷害誘導治療剤
JP2023105929A Withdrawn JP2023123726A (ja) 2017-05-02 2023-06-28 細胞傷害誘導治療剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019559378A Pending JP2020518584A (ja) 2017-05-02 2018-05-02 細胞傷害誘導治療剤

Country Status (4)

Country Link
US (2) US20200123256A1 (enExample)
EP (1) EP3619238A4 (enExample)
JP (2) JP2020518584A (enExample)
WO (1) WO2018203567A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI736437B (zh) 2010-11-30 2021-08-11 日商中外製藥股份有限公司 細胞傷害誘導治療劑
BR112014010257A2 (pt) 2011-10-31 2017-04-18 Chugai Pharmaceutical Co Ltd molécula de ligação ao antígeno tendo conjugação regulada entre cadeias pesadas e cadeias leves
MX380176B (es) 2014-04-07 2025-03-12 Chugai Pharmaceutical Co Ltd Molecula ligada a antigeno inmunoactivada.
KR20170017916A (ko) 2014-05-13 2017-02-15 추가이 세이야쿠 가부시키가이샤 면역 억제 기능을 갖는 세포에 대한 t 세포 리다이렉트 항원 결합 분자
JP6931329B2 (ja) 2015-11-18 2021-09-01 中外製薬株式会社 免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子を用いた併用療法
EP3378488A4 (en) 2015-11-18 2019-10-30 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
SG11201803989WA (en) 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide
JP7617603B2 (ja) 2017-01-11 2025-01-20 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー R-スポンジン(rspo)サロゲート分子
AU2018211985B2 (en) 2017-01-26 2025-02-13 Surrozen Operating, Inc. Tissue-specific Wnt signal enhancing molecules and uses thereof
JP2021530223A (ja) 2018-07-09 2021-11-11 スロゼン, インコーポレイテッド 組織特異性Wntシグナル増強分子及びその使用
JP7359864B2 (ja) 2019-07-10 2023-10-11 中外製薬株式会社 クローディン6結合分子およびその使用
WO2021207613A1 (en) * 2020-04-10 2021-10-14 2Seventy Bio, Inc. Frb antibodies
CN112175080B (zh) * 2020-10-22 2021-05-25 优睿赛思(武汉)生物科技有限公司 抗人白介素-6高亲和力兔单克隆抗体及应用
WO2022104280A1 (en) 2020-11-16 2022-05-19 Surrozen Operating, Inc. Liver-specific wnt signal enhancing molecules and uses thereof
EP4288458A1 (en) * 2021-02-03 2023-12-13 Genentech, Inc. Multispecific binding protein degrader platform and methods of use
US20250171542A1 (en) * 2022-02-28 2025-05-29 Adept Therapeutics Inc. Anti-programmed death-ligand 1 (pd-l1) antibodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE050159T2 (hu) * 2013-12-17 2020-11-30 Genentech Inc Anti-CD3 antitestek és alkalmazási eljárások
BR112016024525A2 (pt) * 2014-04-21 2017-10-10 Abbvie Stemcentrx Llc novos anticorpos anti-rnf43 e métodos de uso
MA40764A (fr) * 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
EP3778640A1 (en) * 2015-05-01 2021-02-17 Genentech, Inc. Masked anti-cd3 antibodies and methods of use

Similar Documents

Publication Publication Date Title
JP2019502712A5 (enExample)
JP2023134618A5 (enExample)
JP2022031635A5 (enExample)
JP2020180158A5 (enExample)
JP2021522162A5 (enExample)
JP2018522541A5 (enExample)
JP2023509448A5 (enExample)
JP2023116744A5 (enExample)
JP2021533159A5 (enExample)
JP2023545057A5 (enExample)
JP2018108081A5 (enExample)
JP2017534577A5 (enExample)
JP2017514461A5 (enExample)
JP2020525032A5 (enExample)
JP2020531438A5 (ja) Nkg2d、cd16、およびhla−eに結合するタンパク質
JP2024520666A5 (enExample)
JP2018527887A5 (enExample)
FI4141032T3 (fi) T-solua aktivoivien bispesifisten antigeeniä sitovien molekyylien ja pd-1-akselia sitovien antagonistien yhdistelmähoito
HRP20240939T1 (hr) Anti-cd3 protutijela i metode uporabe
JP2021520832A5 (enExample)
JP2024542194A5 (enExample)
JP2023548529A5 (enExample)
JP2024541680A5 (enExample)
JP2020502233A5 (enExample)
JP2022529154A5 (enExample)